A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

Trial ID or NCT#

NCT00890552

Status

not recruiting iconNOT RECRUITING

Purpose

This open-label trial will evaluate the use of lenalidomide; melphalan; and dexamethasone (MDR) to treat newly diagnosed or relapsed AL amyloidosis, over the course of nine 28-day cycles.

Official Title

A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Show Less

Contact us to find out if this trial is right for you.

Contact

ccto-office@stanford.edu
650-498-7061

View on ClinicalTrials.gov